STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH

Résultats de recherche: Contribution à un événement scientifique (non publié)Poster

16 Downloads (Pure)

Résumé

Thrombotic diseases, in which a deregulated haemostatic activity occurs, remain a major concern in medicine. Anticoagulants are part of the strategies to address these disorders. However current available drugs are still associated with risk of severe bleeding complications and thus, novel antithrombotics are required1.

In this perspective, coagulation factor XIIa (FXIIa), a serine protease implicated in the coagulation cascade, recently emerged as a promising target in the development of such agents2. Indeed, it was demonstrated that FXII deficiency or inhibition protects against thrombosis without causing spontaneous bleeding in mice3.

Based on these considerations, the aim of our project is to develop novel selective FXIIa inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds could also be a good starting point for the development of new antithrombotic drugs.

The 3-carboxamide coumarins (figure 1) are to date the only nonpetidic and selective inhibitors of FXIIa described in literature4. However, their low solubility and poor pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis. As consequence, we need to improve these characteristics while keeping the selectivity and potency towards FXIIa.

In this work, we first synthesized new coumarins with improved solubility. Their inhibition potency was then measured on FXIIa and finally, their stability was evaluated.
langue originaleAnglais
PagesBook of Abstracts, MedChem 2012, Château de Colonster, Liège - November 30, 2012, P01
Nombre de pages1
étatPublié - 30 nov. 2012
EvénementAnnual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012) - Liège, Belgique
Durée: 30 nov. 2012 → …

Colloque

ColloqueAnnual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012)
PaysBelgique
La villeLiège
période30/11/12 → …

Empreinte digitale

Factor XIIa
Coumarins
Solubility
Thrombosis
Research
Hemorrhage
Serine Proteases
Hemostatics
Pharmaceutical Preparations
Anticoagulants
Pharmacokinetics
Medicine
Enzymes
factor XIIa inhibitor

Citer ceci

Bouckaert, C., Vancraeynest, C., Dolušić, E., Frédérick, R., & Pochet, L. (2012). STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH. Book of Abstracts, MedChem 2012, Château de Colonster, Liège - November 30, 2012, P01. Poster présenté � Annual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012), Liège, Belgique.
@conference{2af18c2b2c4b450aaafaf6b95cd8749c,
title = "STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH",
abstract = "Thrombotic diseases, in which a deregulated haemostatic activity occurs, remain a major concern in medicine. Anticoagulants are part of the strategies to address these disorders. However current available drugs are still associated with risk of severe bleeding complications and thus, novel antithrombotics are required1.In this perspective, coagulation factor XIIa (FXIIa), a serine protease implicated in the coagulation cascade, recently emerged as a promising target in the development of such agents2. Indeed, it was demonstrated that FXII deficiency or inhibition protects against thrombosis without causing spontaneous bleeding in mice3.Based on these considerations, the aim of our project is to develop novel selective FXIIa inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds could also be a good starting point for the development of new antithrombotic drugs. The 3-carboxamide coumarins (figure 1) are to date the only nonpetidic and selective inhibitors of FXIIa described in literature4. However, their low solubility and poor pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis. As consequence, we need to improve these characteristics while keeping the selectivity and potency towards FXIIa.In this work, we first synthesized new coumarins with improved solubility. Their inhibition potency was then measured on FXIIa and finally, their stability was evaluated.",
author = "Charlotte Bouckaert and Christelle Vancraeynest and Eduard Dolušić and Rapha{\"e}l Fr{\'e}d{\'e}rick and Lionel Pochet",
year = "2012",
month = "11",
day = "30",
language = "English",
pages = "Book of Abstracts, MedChem 2012, Ch{\^a}teau de Colonster, Li{\`e}ge -- November 30, 2012, P01",
note = "Annual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012) ; Conference date: 30-11-2012",

}

Bouckaert, C, Vancraeynest, C, Dolušić, E, Frédérick, R & Pochet, L 2012, 'STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH', Annual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012), Liège, Belgique, 30/11/12 p. Book of Abstracts, MedChem 2012, Château de Colonster, Liège - November 30, 2012, P01.

STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH. / Bouckaert, Charlotte; Vancraeynest, Christelle; Dolušić, Eduard; Frédérick, Raphaël; Pochet, Lionel.

2012. Book of Abstracts, MedChem 2012, Château de Colonster, Liège - November 30, 2012, P01 Poster présenté � Annual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012), Liège, Belgique.

Résultats de recherche: Contribution à un événement scientifique (non publié)Poster

TY - CONF

T1 - STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH

AU - Bouckaert, Charlotte

AU - Vancraeynest, Christelle

AU - Dolušić, Eduard

AU - Frédérick, Raphaël

AU - Pochet, Lionel

PY - 2012/11/30

Y1 - 2012/11/30

N2 - Thrombotic diseases, in which a deregulated haemostatic activity occurs, remain a major concern in medicine. Anticoagulants are part of the strategies to address these disorders. However current available drugs are still associated with risk of severe bleeding complications and thus, novel antithrombotics are required1.In this perspective, coagulation factor XIIa (FXIIa), a serine protease implicated in the coagulation cascade, recently emerged as a promising target in the development of such agents2. Indeed, it was demonstrated that FXII deficiency or inhibition protects against thrombosis without causing spontaneous bleeding in mice3.Based on these considerations, the aim of our project is to develop novel selective FXIIa inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds could also be a good starting point for the development of new antithrombotic drugs. The 3-carboxamide coumarins (figure 1) are to date the only nonpetidic and selective inhibitors of FXIIa described in literature4. However, their low solubility and poor pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis. As consequence, we need to improve these characteristics while keeping the selectivity and potency towards FXIIa.In this work, we first synthesized new coumarins with improved solubility. Their inhibition potency was then measured on FXIIa and finally, their stability was evaluated.

AB - Thrombotic diseases, in which a deregulated haemostatic activity occurs, remain a major concern in medicine. Anticoagulants are part of the strategies to address these disorders. However current available drugs are still associated with risk of severe bleeding complications and thus, novel antithrombotics are required1.In this perspective, coagulation factor XIIa (FXIIa), a serine protease implicated in the coagulation cascade, recently emerged as a promising target in the development of such agents2. Indeed, it was demonstrated that FXII deficiency or inhibition protects against thrombosis without causing spontaneous bleeding in mice3.Based on these considerations, the aim of our project is to develop novel selective FXIIa inhibitors to detail the exact role of this enzyme in thrombotic diseases. These compounds could also be a good starting point for the development of new antithrombotic drugs. The 3-carboxamide coumarins (figure 1) are to date the only nonpetidic and selective inhibitors of FXIIa described in literature4. However, their low solubility and poor pharmacokinetics resulted in a lack of activity in in vivo models of thrombosis. As consequence, we need to improve these characteristics while keeping the selectivity and potency towards FXIIa.In this work, we first synthesized new coumarins with improved solubility. Their inhibition potency was then measured on FXIIa and finally, their stability was evaluated.

M3 - Poster

SP - Book of Abstracts, MedChem 2012, Château de Colonster, Liège - November 30, 2012, P01

ER -

Bouckaert C, Vancraeynest C, Dolušić E, Frédérick R, Pochet L. STUDY OF COUMARINS WITH IMPROVED SOLUBILITY TO INHIBIT FXIIa, AN EMERGING TARGET IN THROMBOSIS RESEARCH. 2012. Poster présenté � Annual One-Day Symposium on Medicinal Chemistry of SRC & KVCV (Medchem 2012), Liège, Belgique.